NM Law Qs (PharmExam) Flashcards
Persons who provide acceptable evidence of being currently licensed by examination under the laws of other states in the United
States and the District of Columbia, shall be authorized to practice pharmacy for a period of (90) days from the date on receipt of a
complete application as a Temporary Licensed Pharmacist.
a. True
b. False
Answer: (a) True, [Occupational and Professional Licensing 16.19.3.15].
.
.
.
A. Persons who provide acceptable evidence of being currently licensed by examination under the laws of other states in the United
States and the District of Columbia shall be authorized to practice pharmacy for period of (90) days from the date on receipt of a
complete application and $50.
Fee which will go towards the eventual licensing fee. Persons must become duly licensed in this state within (90) days. The licensing
agency in each state in which the applicant holds or has held a license shall submit a statement to the board confirming the
applicant to be or have been in good standing in that state.
B. The temporary licensee shall not act as the pharmacist-in-charge (unless there is no other pharmacist in the designated facility), a
preceptor, or supervisor of interns or externs.
C. The temporary licensee shall be subject to discipline in the same manner as those holding a full license, and shall be subject to
immediate suspension upon reasonable evidence of false or incorrect statements in the documents submitted or if found not to be
in good standing in other states.
D. The temporary license shall not be renewed or extended.
The data processing system shall have the capacity to produce a daily hard-copy printout of all original prescriptions dispensed and
refilled. This hard-copy printout shall contain:
I. patient name.
II. quantity dispensed.
III. date of issuance of original prescription.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.6.22(B)].
.
.
The computer shall be capable of producing a printout of prescription information within a 72 hour period on demand, with
certification by the practitioner stating it is a true and accurate record. Requested printouts include: patient specific; practitioner
specific; drug specific; or date specific reports.
The printout shall include:
______________________
(1). the original prescription number;
(2). the practitioner’s name;
(3). full name and address of patient;
(4). date of issuance of original prescription order by the practitioner and the date filled;
(5). name, strength, dosage form, quantity of drug prescribed;
(6). total number of refills authorized by the practitioner;
(7). the quantity dispensed is different than the quantity prescribed, then record of the quantity dispensed;
(8). in the case of a controlled substance, the name, address and DEA registration number of the practitioner and the schedule of the
drug;
(9). identification of the dispensing pharmacist; computer-generated pharmacist initials are considered to be the pharmacist of
record unless overridden manually by a different pharmacist who will be the pharmacist of record.
The partial filling of Morphine sulfate for outpatient prescriptions must be done within 72 hours from the initial filling.
a. True
b. False
Answer: (b) False, [New Mexico Administrative Code (NMAC) 16.19.20.46(A),(C)(3)].
.
.
.
A prescription for a controlled substance in Schedule II may be partially filled if the total quantity dispensed in all partial fillings does
not exceed the total quantity prescribed. Remaining portions shall be filled not later than 30 days (Not 72 hours) after the date on
which the prescription is written.
A prescription for a Schedule II controlled substance written for a patient in a Long Term Care Facility (LTCF) or for a patient with a
medical diagnosis documenting a terminal illness may be filled in partial quantities, to include individual dosage units.
(1). If there is any question whether a patient may be classified as having a terminal illness, the pharmacist shall contact the
practitioner prior to partially filling the prescription.
Both the pharmacist and the prescribing practitioner have a corresponding responsibility to assure that the controlled substance is
for a terminally ill patient.
The pharmacist shall record on the prescription whether the patient is “terminally ill” or an “LTCF patient”.
(2). A prescription that is partially filled and does not contain the notation “terminally ill” or LTCF patient” shall be deemed to have
been filled in violation of this regulation. For each partial filling, the dispensing pharmacist shall record on the back of the
prescription (or on appropriate record, uniformly maintained, and readily retrievable) the date of the partial filling, quantity
dispensed, remaining quantity authorized to be dispensed and the identification of the dispensing pharmacist.
(3). The total quantity of Schedule II controlled substances dispensed in all partial fillings shall not exceed the total quantity
prescribed.
Schedule II prescriptions, for patients in a LTCF or patients with a medical diagnosis documenting a terminal illness, shall be valid for
a period not to exceed 60 days from the issue date unless sooner terminated by the discontinuance of medication.
Which of the following shall NOT be classified under an “Automated Filling System”?
I. automated devices used solely to count medication that is then subject to final product check by a pharmacist prior to dispensing.
II. vacuum tube drug delivery systems.
III. automated dispensing and storage systems used to dispense medication directly to a patient.
a. I only
b. I and II only
c. All
d. None of the above
Answer: (c) All, [New Mexico Administrative Code (NMAC) 16.19.6.28(A)].
.
.
.
“Automated filling system” means an automated system used by a pharmacy in the state of New Mexico to assist in filling a
prescription drug order by selecting, labeling, filling, or sealing medication for dispensing.
An “automated filling system” SHALL NOT include automated devices used solely to count medication that is then subject to final
product check by a pharmacist prior to dispensing, vacuum tube drug delivery systems, or automated dispensing and storage
systems used to dispense medication directly to a patient or to an authorized health care practitioner for immediate distribution or
administration to the patient.
Automated filling systems may be stocked or loaded by a pharmacist or by an intern pharmacist or pharmacy technician under the
direct supervision of a pharmacist.
Which of the following statements is/are NOT TRUE about continuing education requirements according to New Mexico State
Pharmacy Law?
I. The pharmacist is required to complete 30 hours of continuing education every two years for renewing his/her license.
II. The pharmacist may obtain these hours by completing courses approved by the ACPE or CME-Category II.
III. A minimum of 0.5 CEUs of the 3.0 CEUs required for registration renewal shall be in the subject area of pharmacy law, as offered
by the N.M. Board of Pharmacy.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (c) II and III are not true, [New Mexico Administrative Code (NMAC) 16.19.4.10].
.
.
.
Continuing pharmacy education, certified as completed by an approved provider will be required of a registered pharmacist who
applies for renewal of New Mexico registration as follows: 3.0 CEU (30 contact hours) every two years.
Effective January 1, 2013, pharmacist and pharmacist clinician renewal applications shall document:
(1). A minimum of 1.0 CEU (10 contact hours) excluding the law requirement , per renewal period shall be obtained through “live
programs” that are approved as such by the ACPE or the accreditation council for continuing medical education (ACCME). Live
programs provided by other providers (such as continuing nursing education) may be acceptable based on review and approval of
the board.
(2). A minimum of 0.2 CEU (2 contact hours) per renewal period shall be in the area of patient safety as applicable to the practice of
pharmacy.
(3). A minimum of 0.2 CEU (2 contact hours) per renewal period shall be in the subject area of pharmacy law offered by the New
Mexico board of pharmacy.
(4). The board of pharmacy will accept CPE education units for programs or activities completed outside the state; provided, the
provider has been approved by the ACPE (NOT CME-II) under its' criteria for quality at the time the program was offered.
(5). Effective January 1, 2015, a minimum of 0.2 CEU (2 contact hours) per renewal period shall be in the area of safe and
appropriate use of opioids. An educational program consisting of a minimum of 0.2 CEU (2 contact hours) that addresses both
patient safety as applicable to the practice of pharmacy and the safe and appropriate use of opioids will satisfy requirements of
Paragraphs (2) and (4) of Subsection B of this section.
(6). Active Status: A minimum of 0.2 CEU (2 contact hours) of the 3.0 CEU (30 contact hours) required for registration renewal shall
be in the subject area pharmacy law as offered by the N.M. board of pharmacy.
In lieu of a board program, pharmacists not residing and not practicing pharmacy in New Mexico, may complete an ACPE accredited
course, in the subject area pharmacy law, meeting the CEU requirements of this paragraph.
(7). Licensees may obtain 0.1 CEU (1 contact hour) per year, in the subject area pharmacy law, by attending one full day of a
regularly scheduled New Mexico board of pharmacy board meeting or serving on a board approved committee.
(8). Licensees who successfully complete an open book test, administered by the board, shall receive credit for 0.2 CEU (2 contact
hours) in the subject area pharmacy law.
Which of the following is/are TRUE about Customized Patient Medication Packages?
I. In lieu of dispensing one, two, or more prescribed drug products in separate containers or standard vial containers, a pharmacist
may, with the consent of the patient, the patient’s care-giver, the prescriber, or the institution caring for the patient, provide a
customized patient medication package.
II. In the event a drug is added to or discontinued from a patient’s drug regimen, the pharmacist may repackage the patient’s patient
medication package and either add to or remove from the patient medication packaged as ordered by the physician.
III. Patient medication packages with more than two drugs within a container may not under any circumstances be returned to a
pharmacy stock.
a. I only
b. I and II only
c. All
d. None of the above
Answer: (b) I and II only, [New Mexico Administrative Code (NMAC) 16.19.4.11(B)(n,o)].
.
.
.
In lieu of dispensing one, two, or more prescribed drug products in separate containers or standard vial containers, a pharmacist
may, with the consent of the patient, the patients care-giver, the prescriber, or the institution caring for the patient, provide a
customized patient medication package.
The pharmacist preparing a patient medication package must abide by the guidelines as set forth in the current edition of the U.S.
Pharmacopoeia for labeling, packaging and record keeping.
In the event a drug is added to or discontinued from a patients drug regimen, when a container within the patient medication
package has more than one drug within it, the pharmacist may repackage the patients patient medication package and either add to
or remove from the patient medication packaged as ordered by the physician.
The same drugs returned by the patient for repackaging must be reused by the pharmacist in the design of the new patient
medication package for the new regimen, and any drug removed must either be destroyed, returned to the DEA or returned to the
patient properly labeled.
Under no circumstances may a drug within a container of a patient medication package which contains more than one drug (Not 2
drugs) be returned to the pharmacy stock.
A patient medication package stored in an institutional setting where the storage and handling of the drugs are assured and are
consistent with the compendia standards may be returned to the pharmacy stock provided the which of following conditions are
met?
I. the drug is to be kept within the patient medication package and it is to remain sealed and labeled until dispensed.
II. the expiration date of drug shall become 50% of the time left of the expiration for the drug.
III. no Schedule II, III or IV drugs may be returned to inventory.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (b) I and II only, [New Mexico Administrative Code (NMAC) 16.19.4.11(B)(p)].
.
.
.
Patient medication packages with more than one drug within a container may not under any circumstances be returned to a
pharmacy stock.
Patient Medication Packages with only one drug within a container:
(1). Non-Institutional: A patient medication package stored in a non-institutional setting where there is no assurance of storage
standards may NOT be returned to pharmacy stock.
(2). Institutional: A patient medication package stored in an institutional setting where the storage and handling of the drugs are
assured and are consistent with the compendia standards may be returned to the pharmacy stock provided the following guidelines
are followed:
(a). the drug is to be kept within the patient medication package and it is to remain sealed and labeled until dispensed;
(b). the expiration date of drug shall become 50% of the time left of the expiration for the drug;
(c). no Schedule II drugs (Schedule III, IV and V are allowed) may be returned to inventory; and
(d). proper record keeping for the addition of other scheduled drugs into inventory must be done.
According to New Mexico State Pharmacy Law, the prescription record should be kept on file for:
a. Two years from the date of dispensing.
b. Five years from the date of dispensing.
c. Three years from the date of dispensing.
d. A year from the date of dispensing.
Answer: (c) According to New Mexico State Pharmacy Law, the original paper prescription document must be maintained for a
minimum of three years and the electronic image of the prescription for ten years, [New Mexico Administrative Code (NMAC)
16.19.6.22(D)(4)].
Any registrant or licensee shall report in writing any change of address or employment to the Board within 30 days.
a. True
b. False
Answer: (b) False, [New Mexico Administrative Code (NMAC) 16.19.4.13].
.
.
.
Any registrant or licensee shall report in writing any change of address or employment to the Board within ten (10) days.
In New Mexico, the inventory of controlled substances should be done every:
a. Year
b. Two years
c. Three years
d. Five years
Answer: (a) Every year, [New Mexico Administrative Code (NMAC) 16.19.20.20(C)].
.
.
.
The annual inventory date shall be May 1 for the initial inventory by the registrant or on the registrant’s regular general physical inventory date, provided that date does not vary by more than 6 months before or after May 1.
The registrant shall notify the Board of Pharmacy of the date on which the annual inventory will be taken, if different from May 1.
The actual taking of the inventory should not vary more than four (4) days from the annual inventory date.
Controlled substances added to the Controlled Substances Act after date of enactment, which substance was, immediately prior to
that date, not listed on any schedule, every registrant who possesses that substance shall take an inventory of all stock of the
substance on hand and file this record with the other inventory records as required.
Who may accept new verbal prescription orders from a licensed physician?
I. a licensed pharmacist
II. a registered pharmacist-intern
III. a certified pharmacy technician
a. I only
b. I and II only
c. II and III only
d. All
Answer: (b) I and II only, [New Mexico Administrative Code (NMAC) 16.19.4.16(A)].
.
.
.
The following responsibilities require the use of professional judgement and therefore shall be performed only by a pharmacist or
pharmacist intern:
(1). receipt of all new verbal prescription orders and reduction to writing;
(2). initial identification, evaluation and interpretation of the prescription order and any necessary clinical clarification prior to
dispensing;
(3). professional consultation with a patient or his agent regarding a prescription;
(4). evaluation of available clinical data in patient medication record system;
(5). oral communication with the patient or patients agent of information, as defined in this section under patient counseling, in
order to improve therapy by ensuring proper use of drugs and devices;
(6). professional consultation with the prescriber, the prescribers agent, or any other health care professional or authorized agent
regarding a patient and any medical information pertaining to the prescription;
(7). drug regimen review, as defined in 61-11-2L;
(8). professional consultation, without dispensing, will require that the patient be provided with the identification of the pharmacist
or pharmacy intern providing the service.
Which of the following acts may be performed by a registered pharmacist-intern?
I. any verbal communication with a patient or patient’s representative regarding a change in drug therapy or performing therapeutic
interchanges.
II. evaluation of pharmaceuticals for formulary selection within the facility.
III. final check on all aspects of the completed prescription including sterile products and cytotoxic preparations.
a. I only
b. I and II only
c. All
d. None of the above
Answer: (d) None of the above, [New Mexico Administrative Code (NMAC) 16.19.4.16(B)].
.
.
.
Only a licensed PHARMACIST shall perform the following duties:
(1). final check on all aspects of the completed prescription including sterile products and cytotoxic preparations, and assumption of
the responsibility for the filled prescription, including, but not limited to, appropriateness of dose, accuracy of drug, strength,
labeling, verification of ingredients and proper container;
(2). evaluation of pharmaceuticals for formulary selection within the facility;
(3). supervision of all supportive personnel activities including preparation, mixing, assembling, packaging, labeling and storage of
medications;
(4). ensure that supportive personnel have been properly trained for the duties they may perform;
(5). any verbal communication with a patient or patients representative regarding a change in drug therapy or performing therapeutic interchanges (i.e. drugs with similar effects in specific therapeutic categories); this does not apply to substitution of
generic equivalents;
(6). any other duty required of a pharmacist by any federal or state law.
If a pharmacist has not been active in the area of pharmacy practice for 3 years, the pharmacist candidate shall do which of the following to reinstate his or her license?
I. submit proof of continuing education for each inactive renewal period.
II. successfully complete the MPJE.
III. submit proof of completed internship of minimum of 60 hours for each year of inactivity.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.2.14(C),(D)].
.
.
.
C. If a pharmacist has not been active in the area of pharmacy practice for greater than one year but less than six years, the pharmacist candidate shall complete the following:
(1). submit renewal form;
(2). pay past renewal fees and reinstatement fees;
(3). submit proof of continuing education for each inactive renewal period;
(4). submit proof of completed internship of minimum of 60 hours for each year of inactivity;
(5). successfully complete the MPJE;
OR
D. In lieu of past renewal fees, reinstatement fees and proof of continuing education an inactive pharmacist may successfully
complete the internship minimum of 60 hours for each year of inactivity, and successfully pass the NAPLEX and the MPJE.
E. If a pharmacist has not been active in the area of pharmacy practice for six years or more, the pharmacist candidate shall:
(1). complete the internship minimum of 60 hours for each year of inactivity; and
(2). successfully pass the NAPLEX and the MPJE.
What are duties of consultant pharmacists?
I. He shall develop the drug control procedures manual.
II. He shall assume responsibility for the destruction or removal of unwanted dangerous drugs and any controlled substances.
III. He shall make routine inspections of drug storage areas, patient health records, and review drug regimen of each patient at least once a month.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.4.11(B)].
.
.
.
(1). The consultant pharmacists agreement with the facility shall include but is not limited to the following duties and
responsibilities.
(a). Serve as a member of appropriate committees, and attend these meetings.
(b). Development of the drug control procedures manual.
(c). Monitor on a routine basis all aspects of the total drug distribution system - to be accomplished in a manner designed to monitor
and safeguard all areas of the drug distribution system.
(d). Maintain active pharmacist status registration in the state.
(e). Assume responsibility for the destruction or removal of unwanted dangerous drugs and any controlled substances as prescribed
by law and regulations.
(f). Maintain a log of all visits and activities in the facility indicating dates and other pertinent data; such logs are to be available to
inspection by state drug inspectors upon request.
(g). Furnish and replenish emergency drug supply in acceptable containers. Maintain a log of use and replacement of drugs in the
emergency tray.
(h). Make routine inspections of drug storage areas, patient health records, and review drug regimen of each patient at least once a
month. Report irregularities, contraindication, drug interactions, etc., to the medical staff.
(i). Provide or make arrangements for provision of pharmacy services to the facility on a 24-hour 7 days a week basis, including stat
orders.
(j). Provide in-service training of staff personnel as outlined in the procedures manual.
(k). Meet all other responsibilities of a consultant pharmacist as set forth in the board regulations and federal or state laws and
which are consistent with quality patient care.
Which of the following statements is/are NOT TRUE about returning patient medication packages, containing more than one drug
within a container, to pharmacy stock in an institutional pharmacy setting?
I. The drug is to be kept within the patient medication package and it is to remain sealed and labeled until dispensed.
II. Schedule III to V drugs may be returned to inventory.
III. The new expiration date of the drug shall become 50% of the time left of the expiration of the drug.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All are not true, [New Mexico Administrative Code (NMAC) 16.19.11.8(B)(7)(k)(m)].
.
.
.
According to New Mexico State Pharmacy Law, patient medication packages with MORE THAN ONE drug within a container may not
under any circumstances be returned to pharmacy stock.
Patient medication packages with only one drug within a container may be returned to pharmacy stock in an institutional pharmacy
setting if the following conditions are met:
1. Non-Institutional: A patient medication package stored in a non-institutional setting where there is no assurance of storage
standards may not be returned to pharmacy stock.
2. Institutional: A patient medication package stored in an institutional setting where the storage and handling of the drugs are
assured and are consistent with the compendia standards may be returned to the pharmacy stock provided the following guidelines
are followed:
(1). The drug is to be kept within the patient medication package and it is to remain sealed and labeled until dispensed;
(2). The expiration date of the drug shall become 50% of the time left of the expiration of the drug;
(3). No Schedule II drugs may be returned to inventory; and
(4). Proper record keeping for the addition of other scheduled drugs into inventory must be done.
The consultant pharmacist whose practice is not in the immediate vicinity of the facility for which he/she has entered into a written
service agreement shall have a written agreement with a local pharmacist to be available on any emergency basis. This said local
pharmacist is known as a co-consultant according to New Mexico State Pharmacy Law.
a. True
b. False
Answer: (a) True, [New Mexico Administrative Code (NMAC) 16.19.4.11(B)(2)(a)-to-(c)].
.
.
.
The consultant pharmacist whose practice is not in the immediate vicinity of the facility for which he/she has entered into a written
service agreement shall have a written agreement with a local pharmacist to be available on any emergency basis.
The consultant pharmacist shall be responsible for the proper training and instruction of such local pharmacist. Said local pharmacist
shall be known as a “co-consultant.”
A copy of these agreements must be filed with the Board of Pharmacy and the facility. Any termination of such agreement shall be
reported in writing within ten (10) days of termination to the Board and to the administrator.
Should a local pharmacist (co-consultant) not be available, the consultant pharmacist must provide an alternative procedure
approved by the Board. If the consultant is also the vendor, then such alternative procedure must reasonably assure rapid delivery
of drugs, medical supplies and pharmacy service to the facility.
In New Mexico, pharmacy permits expire on which of the following dates each year?
a. November 30
b. January 31
c. October 30
d. December 31
Answer: (d) In New Mexico, a pharmacy permit expires on December 31 of each year, [New Mexico Administrative Code (NMAC)
16.19.6.20(D)].
Which of the following is/are TRUE about a licensed pharmacist clinician according to New Mexico State Pharmacy Law?
I. An applicant must complete a sixty-hour Board-approved physical assessment course.
II. An applicant must complete a 150-hour, 300 patient contact preceptorship supervised by a physician or other practitioner with
prescriptive authority.
III. A pharmacist clinician may prescribe controlled substance listed in Schedule II or Schedule III.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.4.17(B)].
.
.
.
The Board may certify and register a pharmacist as a pharmacist clinician upon completion of an application for certification and
satisfaction of the following requirements.
To obtain initial certification and registration as a pharmacist clinician, she/he must submit the following:
(a). proof of completion of sixty (60) hour board approved physical assessment course, followed by a 150 hour, 300 patient contact
preceptorship supervised by a physician or other practitioner with prescriptive authority, with hours counted only during direct
patient interactions;
(b). the applicant will submit a log of patient encounters as part of the application;
(c). patient encounters must be initiated and completed within 2 years of the application;
(d). a pharmacist clinician requesting a controlled substance registration to prescribe controlled substance in Schedule II or Schedule
III shall be trained in responsible opioid prescribing practices.
Educational programs shall include an understanding of the pharmacology and risks of controlled substances, a basic awareness of
the problems of abuse, addiction, and diversion, and awareness of the state and federal regulations of the prescribing of controlled
substances.
What are the requirements to become a certified preceptor according to New Mexico State Pharmacy Law?
I. An applicant has been actively engaged in the practice of pharmacy for one year.
II. An applicant has not been convicted of violation of any laws or regulations relating to pharmacy in any states.
III. An applicant has been working for at least 25 hours per week to qualify to become a licensed preceptor.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (b) I and II are true, [New Mexico Administrative Code (NMAC) 16.19.5.8(D)].
.
.
.
Requirements for Preceptor:
________________________
Each Preceptor shall:
(1). Be certified as a preceptor by the Board or be an approved preceptor for intern training in another state, by that state Board of
Pharmacy.
(2). Have been actively engaged in the practice of pharmacy for one year.
(3). Be engaged in full-time (NOT PART-TIME) practice of pharmacy.
(4). Not have been convicted of violation of any laws or regulations relating to pharmacy, unless this provision is waived by the
Board on an individual basis.
(5). Submit all required forms, affidavits, and evaluations to the Board on or before the due date.
(6). Notify the Board of any change of address or employment in writing, within ten (10) days. Change of employment shall serve to
suspend certification as preceptor in the former place of employment where the individual was training as an intern.
Prior to dispensing any prescription, a pharmacist shall review the patient profile for the purpose of identifying:
I. therapeutic duplication.
II. drug-drug interactions.
III. incorrect duration of drug treatment.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.4.16(D)].
.
.
.
Prior to dispensing any prescription, a pharmacist shall review the patient profile for the purpose of identifying:
(a). clinical abuse/misuse;
(b). therapeutic duplication;
(c). drug-disease contraindications;
(d). drug-drug interactions;
(e). incorrect drug dosage;
(f). incorrect duration of drug treatment;
(g). drug-allergy interactions;
(h). appropriate medication indication.
If any person knows or suspects that a licensee is impaired, that person shall report any relevant information to:
I. Impaired Pharmacist Program
II. Board of Pharmacy
III. District Pharmacist Manager (DPM)
a. I only
b. I and II only
c. II and III only
d. All
Answer: (b) I and II only, [New Mexico Administrative Code (NMAC) 16.19.4.12(C)].
If any person knows or suspects that a licensee is impaired, that person shall report any relevant information either to the Impaired
Pharmacist Program or to the Board of Pharmacy ("Board").
When the Board receives an initial report relating to an alleged impaired Board licensee, that authority may:
(i). refer the licensee to the Impaired Pharmacist Program for verification, intervention and subsequent evaluation and/or
treatment; or
(ii). verify the information provided on the alleged impaired licensee and assume the responsibility for intervention and referral for
evaluation and/or treatment; or
(iii). file a complaint to initiate disciplinary action.
The names of voluntary participants in the program and records relating to their referral and treatment are confidential pursuant to
Section 61-11A-3 and Section 61-11A-7, provided, however, that this information may be disclosed:
(a). in a disciplinary hearing before the Board and in court proceedings arising therefrom;
(b). to the Board and to the pharmacist's licensing/disciplinary authorities of other jurisdictions in accordance with law;
(c). pursuant to an order of a court of competent jurisdiction;
(d). injunctive proceedings brought by the Board; and
(e). as otherwise provided by law.
Impaired Pharmacist - a pharmacist who is unable to practice pharmacy with reasonable skill, competence or safety to the public
because of drug abuse, and/or mental illness, the aging process or loss of motor skills, sight or hearing.
When medications are prescribed and dispensed by the physician to the patient in the emergency room of the hospital, the
dispensing label shall contain all of the following information EXCEPT:
a. the name and address of the hospital
b. date the drug is dispensed
c. the name or initial of the dispensing pharmacist
d. the name of the patient
Answer: (c) the name or initial of the dispensing pharmacist, [New Mexico Administrative Code (NMAC) 16.19.7.11(L)(4)].
.
.
.
When medications are prescribed by the physician and dispensed to the patient in the emergency room of the hospital the
dispensing label shall contain the following information:
(a). the name of the patient;
(b). the name of the prescribing/dispensing physician (NOT the pharmacist);
(c). name of the drug;
(d). strength of the drug;
(e). quantity of the drug;
(f). name and address of the hospital;
(g). date the drug is dispensed;
(h). directions for use;
(i). expiration date of medication.
Which of the following is/are TRUE about refilling a prescription drug or device when the pharmacist fails to obtain authorization
from the prescriber?
I. A pharmacist can fill the prescription drug or device if he thinks that the drug or device is required for continuation of therapy for
chronic conditions.
II. A pharmacist can fill the prescription drug or device if he thinks that the interruption of the therapy may produce serious health
consequences.
III. A pharmacist can only fill the prescription drug if the refill of the prescription is not for a controlled substance.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (b) I and II are true, [Controlled Substances Act Chapter 61 Article 11 Section 7(A)(9)].
.
.
.
The pharmacist may fill the prescription drug (including controlled substances) or device when he fails to obtain authorization from
the prescriber if he thinks that:
1. The drug or device is essential for continuation of therapy for chronic conditions.
2. The interruption of the therapy may produce serious health consequences.
3. The pharmacist is unable to contact the licensed practitioner after reasonable effort.
4. The quantity of prescription drug dispensed does not exceed a seventy-two-hour (72-hour) supply.
5. The pharmacist informs the patient or the patient's agent at the time of dispensing that the refill is being provided without such
authorization and that authorization of the licensed practitioner is required for future refills.
6. The pharmacist informs the licensed practitioner of the emergency refill at the earliest reasonable time.
Which of the following statements are TRUE about pharmacist intern requirements according to New Mexico State Pharmacy Law?
I. A maximum of 40 hours per week shall be considered computed time for the purpose of completing the internship requirement of
1500 hours.
II. An applicant for registration as a pharmacist intern shall have satisfactorily completed not less than 30 semester hours or the
equivalent from the ACPE-approved pharmacy college.
III. The intern shall notify the Board of any change of address, employment or preceptor, in writing, within ten (10) days of such
change.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (c) II and III are true, [New Mexico Administrative Code (NMAC) 16.19.5.8(E)].
Requirements for Intern:
______________________
(1). Application shall be made to the Board on the required application form provided by the Board prior to the beginning of the
internship.
An applicant for registration as a pharmacist intern shall have satisfactorily completed not less than 30 semester hours or the
equivalent thereof, in a college of pharmacy curriculum accredited from the ACPE-approved pharmacy college.
(2). The intern shall wear the standard identification tag, approved and issued by the Board, during any pharmacy area employment.
(3). Employment and the internship training period are not to be interpreted as being the same. An intern may work in excess of his
computed time. A maximum of 48 hours (NOT 40 hours) per week, however, shall be considered computed time for the purpose of
completing the internship requirement of 1500 hours.
(4). The intern shall notify the Board of any change of address, employment or preceptor, in writing, within ten (10) days of such
change.
(5). The intern certificate of registration and renewal shall be displayed in the training area where the intern is employed.
The intern registration must be renewed annually on/or before the last day of September.
For pharmacies delivering more than fifty percent of their prescriptions by mail or other common carrier, the hours of availability for
counseling shall be a minimum of 60 hours per week and not less than six days per week.
a. True
b. False
Answer: (a) True, [New Mexico Administrative Code (NMAC) 16.19.4.16(F)(6)(7)].
.
.
.
When the patient or agent is not present when the prescription is dispensed including, but not limited to, a prescription that was
shipped by the mail, the pharmacist shall ensure that the patient receives written notice of available counseling. Such notice shall
include days and hours of availability, and:
(1). of his or her right to request counseling; and
(2). a toll-free telephone number in which the patient or patient's agent may obtain oral counseling from a pharmacist who has
ready access to the patient's record.
For pharmacies delivering more than fifty percent of their prescriptions by mail or other common carrier, the hours of availability
shall be a minimum of 60 hours per week and not less than six days per week. The facility must have sufficient toll-free phone lines
and personnel to provide counseling within 15 minutes.
In every pharmacy there shall be prominently posted in a place conspicuous to and readable by prescription drug consumers a
notice concerning available counseling.
A pharmacist shall request and review a prescription monitoring report covering at least a one year time period and another states’
report, where applicable and available if:
I. a pharmacist becomes aware of a person appears overly sedated or intoxicated upon presenting a prescription for an opiate.
II. a pharmacist receives an opiate prescription requesting the dispensing of opiates from a prescription issued by a prescriber with whom the pharmacist is unfamiliar.
III. a pharmacist providing opiates for a patient that is receiving chronic pain management prescriptions.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.4.16(E)].
.
.
.
Prescription monitoring report for opiate prescriptions: When presented with an opiate prescription for a patient, obtaining and
reviewing a prescription monitoring report for that patient can be an important tool that assists the pharmacist in identifying issues
or problems that put his or her patient at risk of prescription drug abuse or diversion.
A pharmacist shall use professional judgment based on prevailing standards of practice in determining whether to obtain and review
a prescription monitoring report before dispensing an opiate prescription to that patient, and shall document his or her action
regarding such reports.
(1). A pharmacist shall request and review a prescription monitoring report covering at least a one year time period and another
states’ report, where applicable and available if;
(a). a pharmacist becomes aware of a person currently exhibiting potential abuse or misuse of opiates (i.e. over-utilization, early
refills, multiple prescribers, appears overly sedated or intoxicated upon presenting a prescription for an opiate or an unfamiliar
patient requesting an opiate by specific name, street name, color, or identifying marks, or paying cash when the patient has
prescription insurance);
(b). a pharmacist receives an opiate prescription requesting the dispensing of opiates from a prescription issued by a prescriber with
whom the pharmacist is unfamiliar (e.i. prescriber is located out-of-state or prescriber is outside the usual pharmacy geographic
prescriber care area);
(c). providing opiates for a patient that is receiving chronic pain management prescriptions.
(2). After obtaining an initial prescription monitoring report on a patient, a pharmacist shall use professional judgment base on
prevailing standards of practice, in deciding the frequency of requesting and reviewing further prescription monitoring reports and
other states’ reports for that patient. The pharmacist shall document the review of these reports.
(3). In the event a report is not immediately available, the pharmacist shall use professional judgment in determining whether it is
appropriate and in the patient’s best interest to dispense the prescription prior to receiving a report.
(4). A prescription for an opiate written for a patient in a long term care facility (LTCF) or for a patient with a medical diagnosis
documenting a terminal illness is exempt from Subsection D of 16.19.29.8 NMAC.
If there is any question whether a patient may be classified as having a terminal illness, the pharmacist shall contact the practitioner.
The pharmacist shall document whether the patient is “terminally ill” or an “LTCF patient”.
Which of the following is/are classified as Schedule IV controlled drug(s)?
I. Barbital
II. Meprobamate
III. Paraldehyde
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [Controlled Substances Act Chapter 30 Article 31 Section 9].
.
.
.
List of Schedule IV controlled drugs:
______________________________
Carisoprodol (Soma)
Tramadol (Ultram)
Alprazolam (Xanax)
Barbital (Barbitone)
Butorphanol (Stadol, Stadol NS, Torbugesic, Torbutrol)
Chloral hydrate (Noctec)
Chlordiazepoxide (Librium, Libritabs, Limbitrol, SK-Lygen)
Clonazepam (Klonopin, Clonopin)
Clorazepate(Tranxene)
Dexfenfluramine (Redux)
Diazepam (Valium, Valrelease)
Dichloralphenazone (Midrin)
Difenoxin 1 mg/ Atropine 25 mcg (Motofen)
Estazolam (ProSom, Domnamid, Eurodin, Nuctalon)
Ethchlorvynol (Placidyl)
Fenfluramine (Pondimin, Ponderal)
Flurazepam (Dalmane)
Fospropofol (Lusedra)
Lorazepam (Ativan)
Mazindol (Sanorex, Mazanor)
Meprobamate (Miltown, Equanil, Deprol, Equagesic, Meprospan)
Midazolam (Versed)
Modafinil (Provigil)
Oxazepam (Serax, Serenid-D)
Paraldehyde
Pemoline (Cylert)
Pentazocine (Talwin, Talwin NX, Talacen, Talwin Compound)
Phenobarbital (Luminal, Donnatal, Bellergal-S)
Phentermine (Ionamin, Fastin, Adipex-P, Obe-Nix, Zantryl)
Prazepam (Centrax)
Propofol (Diprivan)
Propoxyphene dosage forms with other ingredients
Quazepam (Doral, Dormalin)
Sibutramine (Meridia)
Temazepam (Restoril)
Triazolam (Halcion)
Zaleplon (Sonata)
Zolpidem (Ambien)
Zopiclone (Imovane)
Eszopiclone (Lunesta)
Which of the following is/are TRUE ABOUT Remote Pharmacy Technician Data Entry Sites?
I. All pharmacy technicians employed to work at a remote data entry practice site must be registered as a certified pharmacy
technician with the board and have a minimum of one year experience performing data entry functions as a certified pharmacy tech.
II. A New Mexico licensed pharmacy located in New Mexico may employ one or more certified pharmacy technicians for the purpose
of data input in remote practice sites.
III. Only non-controlled drug inventory shall be kept at any remote pharmacy technician data entry site.
a. I only
b. I and II only
c. All
d. None of the above
Answer: (b) I and II only, [New Mexico Administrative Code (NMAC) 16.19.6.29].
.
.
.
A. General requirements:
(1). A New Mexico licensed pharmacy located in New Mexico may employ one or more certified pharmacy technicians for the
purpose of data input in remote practice sites provided that all security requirements are met.
(2). All pharmacy technicians employed to work at a remote data entry practice site must be registered as a certified pharmacy
technician with the board and have a minimum of one year experience performing data entry functions as a certified pharmacy tech.
(3). All remote pharmacy technician data entry sites will operate under a New Mexico licensed pharmacy located in New Mexico
under the authority of its pharmacist-in-charge.
(4). No drug inventory shall be kept at any remote pharmacy technician data entry site and no dispensing shall take place from a
remote pharmacy technician data entry site.
(5). All remote pharmacy technician data entry sites will have a procedure for identifying the pharmacy technician and the
pharmacist responsible for each aspect of the prescription preparations.
(6). All remote pharmacy technician data entry sites will have quality monitoring and improvement programs in place.
Which of the following is/are classified as Schedule II controlled drug(s)?
I. Heroin
II. Hydrocodone
III. Alfentanil
a. I only
b. I and II only
c. II and III only
d. All
Answer: (c) Hydrocodone and Alfentanil are classified as Schedule II controlled drugs, [Controlled Substances Act Chapter 30 Article
31 Section 7]. Heroin is classified as a Schedule I controlled drug, [Controlled Substances Act Chapter 30 Article 31 Section 6].
.
.
.
List of Schedule II controlled drugs:
_____________________________
Alfentanil (Alfenta)
Amobarbital (Amytal, Tuinal)
Amphetamine (Dexedrine, Biphetamine)
Lisdexamfetamine (Vyvanse)
Coca Leaves
Cocaine
Codeine
Dextropropoxyphene, bulk (non-dosage forms)
Dihydrocodeine (Didrate, Parzone)
Diphenoxylate
Diprenorphine
Ecgonine (Cocaine precursor, in Coca leaves)
Ethylmorphine (Dionin)
Fentanyl (Innovar, Sublimaze, Duragesic)
Glutethimide (Doriden, Dorimide)
Hydrocodone (dihydrocodeinone)
Hydrocodone and isoquinoline alkaloid
Hydrocodone combination product (Tussionex, Tussend, Lortab, Vicodin, Hycodan, Anexsia)
Hydromorphone (Dilaudid, dihydromorphinone)
Levo-Alphacetylmethadol (LAAM, long acting methadone, levomethadyl acetate)
Meperidine (Demerol, Mepergan, pethidine)
Methadone (Dolophine, Methadose, Amidone)
Methamphetamine (Desoxyn, D-desoxyephedrine, ICE, Crank, Speed)
Methylphenidate (Ritalin)
Morphine (MS Contin, Roxanol, Duramorph, RMS, MSIR)
Opium poppy
Opium tincture
Opium, granulated
Opium, powdered
Opium, raw
Oxycodone (OxyContin, Percocet, Tylox, Roxicodone, Roxicet)
Oxymorphone (Numorphan)
Pentobarbital (Nembutal)
Poppy Straw Concentrate
Remifentanil (Ultiva)
Secobarbital (Seconal, Tuinal)
Sufentanil (Sufenta)
Tapentadol (Nucynta)
Which of the following is/are TRUE about a hospital pharmacy that utilizes another licensed pharmacy/pharmacist to provide
pharmaceuticals and/or other pharmacist services?
I. the pharmacist providing the services by the contracted pharmacy shall be licensed as a pharmacist in the state where the
contracted pharmacy is located.
II. the contracted pharmacy/pharmacist must have complete access to the patient’s profile in order to perform a drug regimen
review.
III. the contracted pharmacy/pharmacist must have access to the licensed practitioners of the hospital.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (c) II and III only, [New Mexico Administrative Code (NMAC) 16.19.7.11(N)].
.
.
.
Outsourcing of Pharmaceutical Services: A hospital pharmacy may contract or enter into an agreement with another licensed
pharmacy/pharmacist to provide pharmaceuticals and/or other pharmacist services under the following conditions:
(1). the contract pharmacy is licensed by the board of pharmacy;
(2). the pharmacist providing the services by the contracted pharmacy shall be licensed as a pharmacist in this state (not in the state
where contracted pharmacy is located);
(3). the contract is incorporated into the pharmacy’s policy and procedure manual and complies with the requirements of 16.19.7
NMAC;
(4). the contracted pharmacy/pharmacist must have complete access to the patient’s profile in order to perform a drug regimen
review;
(5). the contracted pharmacy/pharmacist must have access to the licensed practitioners of the hospital;
(6). records of all pharmaceuticals transferred from the contracted pharmacy to the hospital pharmacy comply with the
requirements;
(7). documentation of the services provided by the contracted pharmacy/pharmacist.
Which of the following is/are TRUE about patient counseling?
I. An offer to counsel shall be made to each patient or caregiver when the pharmacist fills, delivers or sends a new retail or
outpatient prescription.
II. A mail order pharmacy shall make the offer to counsel either by telephone or by sending a written offer together with the filled
prescription.
III. If the pharmacist, in the exercise of professional judgment in the interest of a patient, believes that an oral offer would be less
effective than a written offer, the pharmacist may substitute a written offer.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.7.16(F)].
.
.
.
An offer to counsel shall be made to each patient or caregiver when the pharmacist fills, delivers or sends a new retail or outpatient
prescription.
Patient counseling, as described above and defined in this regulation shall not be required for in-patients of a hospital or institution
where other licensed health care professionals are authorized to administer the drug(s).
The pharmacist or designee of the pharmacist shall orally make the offer in person if a patient or caregiver comes to the pharmacy.
If the pharmacist, in the exercise of professional judgment in the interest of a patient, believes that an oral offer would be less
effective than a written offer, the pharmacist may substitute a written offer.
The following are examples of situations in which a pharmacist might substitute a written offer:
(1). The patient or caregiver is hearing impaired.
(2). The patient or caregiver is not an English speaker.
If neither the patient nor caregiver comes to the pharmacy, the offer to counsel shall be made in one of the following ways:
(1). The pharmacist or designee may telephone the patient or caregiver.
(2). The pharmacy delivery person may orally make the offer to the patient or caregiver.
(3). The pharmacist may send a written offer to counsel together with the filled prescription, which is delivered or sent to the
patient.
(4). A written offer to counsel shall include the telephone number of the pharmacy.
(5). A pharmacy shall provide toll-free telephone service if its primary patient population is beyond the local or toll-free exchange.
(6). A mail order pharmacy shall make the offer to counsel either by telephone or by sending a written offer together with the filled
prescription.
The written offer shall include a toll-free telephone number of the pharmacy which a patient or caregiver may use to obtain
counseling.
Upon termination of the pharmacist-in-charge, each pharmacy owner shall immediately designate a successor pharmacist-in-charge
and immediately notify the state Board of Pharmacy within 10 days.
a. True
b. False
Answer: (a) True, [New Mexico Administrative Code (NMAC) 16.19.6.9(C)].
Upon termination of the pharmacist-in-charge, each pharmacy owner shall immediately designate a successor pharmacist-in-charge
and immediately notify the state Board of Pharmacy of such designation.
The owner shall request the license application form to be completed by the successor pharmacist-in-charge and filed with the
Board within 10 days.
The failure to designate a successor pharmacist-in-charge and notify the Board of such designation shall be deemed a violation of
the New Mexico Pharmacy Act.
Which of the following is required to order Schedule I and Schedule II controlled drugs?
a. DEA 222
b. DEA 106
c. DEA 41
d. DEA 351
Answer: (a) Schedule I and II controlled drugs can be ordered by filling out a DEA 222 form, [New Mexico Administrative Code
(NMAC) 16.19.20.26].
.
.
.
Each form contains three copies (i.e. Copy 1, Copy 2 and Copy 3). The purchaser completes the form and submits the Copy 1 and
Copy 2 of the form to the supplier, and retains Copy 3 for his/her own record.
The partially filled order must be filled within 60 days from the date of issuance. The order form is no longer valid after 60 days from
the time it was executed by purchaser.
A pharmacist is adding 1000 mg of pure codeine powder to 100 cc of Tylenol with codeine Elixir (120 mg/12 mg/5 cc). The resultant
mixture should be classified as:
a. Schedule II
b. Schedule III
c. Schedule IV
d. Schedule V
Answer: (b) The compounded mixture should be classified as a Schedule III controlled drug. The amount of Codeine present in the
final mixture is 1.24 gms (1000 mg plus 240 mg), [Controlled Substances Act Chapter 30 Article 31 Section 8(D)(2)].
It has been stated under CSA that if a mixture contains less than 1.8 gms of Codeine per 100 cc, it should be classified as a Schedule
III controlled substance.
List of Schedule III controlled drugs:
______________________________
Butalbital (Fiorinal and [Fioricet only for New Mexico])
Amobarbital and noncontrolled active ingredients
Amobarbital suppository dosage form
Anabolic steroids
Barbituric acid derivative
Benzphetamine (Didrex, Inapetyl)
Buprenorphine (Buprenex, Temgesic)
Butabarbital (Butisol, Butibel)
Codeine and isoquinoline alkaloid (Codeine with papaverine or noscapine)
Codeine combination product (Empirin, Fiorinal, Tylenol, ASA or APAP w/codeine)
Dronabinol in sesame oil in soft gelatin capsule (Marinol)
Gamma-hydroxybutyric acid
Ketamine
Lysergic acid
Lysergic acid amide
Methyltestosterone (Android, Oreton, Testred, Virilon)
Nalorphine (Nalline)
Nandrolone (Deca-Durabolin, Durabolin, Durabolin-50)
Norethandrolone(Nilevar, Solevar)
Opium combination product (Paregoric)
Pentobarbital and noncontrolled active ingredients
Pentobarbital suppository dosage form
Phendimetrazine (Bontril)
Secobarbital and noncontrolled active ingredients
Secobarbital suppository dosage form
Sodium oxybate (Xyrem)
Testosterone (Android-T, Androlan, Depotest, Delatestryl)
Thiopental (Pentothal)
According to New Mexico State Pharmacy Law, a biological safety cabinet must be certified by an independent qualified contractor
prior to use and at six-month intervals; certification records will be maintained for 1 year.
a. True
b. False
Answer: (b) False, [New Mexico Administrative Code (NMAC) 16.19.36.10(B)].
.
.
.
All compounded sterile products for human use shall be prepared in an appropriate aseptic environment which meets USP-797
standards. Devices used to provide an aseptic environment including laminar air flow workbenches, biological safety cabinets,
compounding aseptic isolators and compounding aseptic containment isolators will:
(a). be tested in the course of normal operation by an independent qualified contractor and certified as meeting the requirements
presented in USP-797 at least every 6 months and when relocated, certification records will be maintained for 3 years (Not 1 year);
(b). have pre-filters which are inspected periodically and inspection/replacement date documented according to written policy.
A pharmacist shall not be required to counsel a patient or care giver when the patient or care giver refuses such consultation and such refusal is documented.
a. True
b. False
Answer: (a) True, [New Mexico Administrative Code (NMAC) 16.19.4.16(F)(5)].
.
.
.
A pharmacist shall in no way attempt to circumvent or willfully discourage a patient or patients agent from receiving counseling.
However, a pharmacist shall not be required to counsel a patient or patient’s agent when the patient or patient’s agent refuses such
consultation.
Phenergan with Codeine syrup is classified as:
a. Schedule II
b. Schedule III
c. Schedule IV
d. Schedule V
Answer: (d) Phenergan with Codeine syrup is classified as a Schedule V controlled drug, [Controlled Substances Act Chapter 30
Article 31 Section 10].
List of Schedule V controlled drugs:
______________________________
Codeine preparations - 200 mg per 100 ml or 100 gm (Robitussin AC, Phenergan with Codeine)
Difenoxin preparations - 0.5 mg Difenoxin + 25mcg Atropine sulfate (Motofen)
Dihydrocodeine preparations 100 mg per 100 ml or 100 gm
Diphenoxylate preparations- 2.5 mg Diphenoxylate + 25mcg Atropine sulfate (Lomotil, Logen)
Ethylmorphine preparations 100 mg per 100 ml or 100 gm
Opium preparations - 100 mg per 100 ml or gm (Parepectolin, Kapectolin PG, Kaolin Pectin P.G.)
Pseudoephedrine
Lyrica - Pregabalin
Vimpat - Lacosamide
Potiga - Ezogabine
Automated compounding devices shall:
I. have accuracy verified on a routine basis at least every 30 days per manufacturer’s specifications.
II. be observed every 30 days by the operator during the mixing process to ensure the device is working properly.
III. have accurate final documentation of compounded preparations to allow for verification of ingredients by a pharmacist prior to
dispensing.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.36.10(D)].
.
.
.
Automated compounding devices shall:
(1). have accuracy verified on a routine basis at least every 30 days per manufacturers specifications;
(2). be observed every 30 days by the operator during the mixing process to ensure the device is working properly;
(3). have data entry verified by a pharmacist prior to compounding or have accurate final documentation of compounded
preparations to allow for verification of ingredients by a pharmacist prior to dispensing; and
(4). have accuracy of delivery of the end product verified according to written policies and procedures.
Which of the following information about Pharmacist-In-Charge in hospital pharmacies is/are TRUE?
I. The pharmacist in charge may be employed part-time or full-time as the activity of service requires.
II. When services are provided on a part-time basis, the pharmacist-in-charge or designated pharmacist shall visit the facility at least
every 72 hours.
III. A pharmacy policy and procedure manual shall be reviewed by the pharmacist-in-charge annually for the purpose of establishing
its consistency with current hospital practices and the process documented.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.7.8].
.
.
.
A. There shall be a pharmacist-in-charge of the hospital pharmacy. The pharmacist in charge may be employed part-time or full-time
as the activity of service requires. When services are provided on a part-time basis, the pharmacist-in-charge or designated
pharmacist shall visit the facility at least every 72 hours. Visitation schedules exceeding 72 hours must request Board approval.
B. The pharmacist-in-charge shall be assisted by an adequate number of competent and qualified personnel.
C. Written job descriptions for all categories of pharmacy personnel shall be prepared and revised as necessary.
D. A pharmacy policy and procedure manual shall be prepared by the pharmacist-in-charge and readily available. The manual shall
be reviewed annually for the purpose of establishing its consistency with current hospital practices and the process documented.
A copy of this manual shall be submitted to the Board or its agent for review and approval at the time of the hospital license
application. Any subsequent changes shall be reviewed by the Board or its agent
In emergency situations, pharmacist clinicians may prescribe dangerous drugs including controlled substances for self-treatment or
treatment of immediate family members.
a. True
b. False
Answer: (a) True, [New Mexico Administrative Code (NMAC) 16.19.4.17(D)(5)].
.
.
.
Pharmacist clinicians shall not prescribe dangerous drugs including controlled substances for self-treatment or treatment of
immediate family members, except under emergency situations.
This will not apply to pharmacist administered vaccinations.
Pharmacist clinicians shall not write a recommendation for the use of medical cannabis.
A pharmacy service unit:
I. is a separate entity from the central hospital pharmacy, within the same physical building.
II. provides limited and/or specialized inpatient pharmacy services with a minimum of 100 square feet.
III. shall be covered by the hospital pharmacy license.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.7.10].
.
.
.
A. A pharmacy service unit:
(1). is a separate entity from the central hospital pharmacy, within the same physical building;
(2). provides limited and/or specialized inpatient pharmacy services with a minimum of 100 square feet;
(3). has the necessary space, references and equipment to perform the pharmacy service to be provided.
B. If controlled substances are stored in and/or dispensed from the Pharmacy Service Unit, a locked storage space must be provided
and used to store all controlled substances.
C. The Pharmacy Service Unit shall be covered by the hospital pharmacy license.
D. A pharmacist shall be available to the Pharmacy Service Unit during operational hours.
E. A pharmacist shall control access to the Pharmacy Service Unit. Pharmacy technician(s) or intern(s) may be present in the
Pharmacy Service Unit during operational hours when the pharmacist is present in the facility.
Which of the following information is/are True under New Mexico State Pharmacy Law?
I. In hospitals without a pharmacy, prelabeled, prepackaged medications shall be stored in and distributed from a drug storage area
or automated medication management system.
II. All medications shall be issued for inpatients use pursuant to the review of the physicians order or direct copy thereof, prior to
dispensing.
III. If the hospital pharmacy is closed when the order is written; the pharmacist shall review the order within 72 hrs.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (b) I and II are true, [New Mexico Administrative Code (NMAC) 16.19.7.11(A) To (C)].
.
.
.
A. In hospitals without a pharmacy, prelabeled, prepackaged medications shall be stored in and distributed from a drug storage area
or automated medication management system, which is under the supervision of a pharmacist.
B. The pharmacist-in-charge shall have the responsibility for the procurement and storage of all drugs.
C. All medications, with the exception of those for emergency use, shall be issued for inpatients use pursuant to the review of the
physicians order or direct copy thereof, prior to dispensing. If the pharmacy is closed when the order is written, the pharmacist shall
review the order within 24 hrs (Not 72 hours).
Which of the following is/are required to renew pharmacist clinician registration?
I. A pharmacist clinician shall complete 20 contact hours of live CPE or continuing medical education (CME) approved by (ACPE) or
AACME.
II. A pharmacist clinician shall provide a current protocol of collaborative practice signed by the supervising physician.
III. A pharmacist clinician with a controlled substance registration to prescribe controlled substances listed in Schedule II or Schedule
III shall complete a minimum of 8 contact hours per renewal period in the subject area of responsible opioid prescribing practices.
a. I only
b. I and II only
c. All
d. None of the above
Answer: (b) I and II only, [New Mexico Administrative Code (NMAC) 16.19.4.17(C)].
.
.
.
Biennial renewal of pharmacist clinician registration:
(1). Renewal applications shall be submitted prior to the license expiration.
(2). Applications for renewal must include:
(a). Documentation of continuing education hours, including proof of completion of 2.0 CEU 20 contact hours of live CPE or
continuing medical education (CME) approved by (ACPE) or AACME and
(b). A pharmacist clinician with a controlled substance registration to prescribe controlled substances listed in Schedule II or
Schedule III shall complete a minimum of 0.2 CEU (two contact hours) per renewal period in the subject area of responsible opioid
prescribing practices, and
(c). a current protocol of collaborative practice signed by the supervising physician and
(d). a copy of the pharmacist clinicians registration with the supervising physicians board and
(e). other additional information as requested by the board.
Who may dispense drugs in a hospital emergency room?
I. a licensed prescriber
II. a licensed pharmacist
III. a licensed pharmacist intern
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.7.11(L)].
.
.
.
L. Medications dispensed in the emergency room will be dispensed only by a licensed pharmacist, a licensed pharmacist intern or a
licensed practitioner and shall comply with the following:
(1). a record shall be kept of all medications dispensed from the emergency room of a hospital; the record shall include:
(a). the date the drug was dispensed;
(b). name and address of the patient;
(c). name of the prescribing physician;
(d). the name of the drug;
(e). the strength of the drug;
(f). the quantity of drug dispensed;
(g). initials of the person recording the information if not a physician;
(2). a separate record shall be kept for schedule II controlled substances;
(3). the following will be recorded in the patients medical chart:
(a). the name of the drug(s) prescribed;
(b). the strength of the drug;
(c). the quantity of the drug dispensed;
(4). when medications are prescribed by the physician and dispensed to the patient in the emergency room of the hospital the
dispensing label shall contain the following information:
(a). the name of the patient;
(b). the name of the prescribing physician;
(c). name of the drug;
(d). strength of the drug;
(e). quantity of the drug;
(f). name and address of the hospital;
(g). date the drug is dispensed;
(h). directions for use;
(i). expiration date of medication.
Floor stock drugs, including those issued from automated medication management systems, shall be limited to drugs for emergency
use and routinely used items as listed in the pharmacy policy and procedure manual and approved by the pharmacy and
therapeutics committee.
Floor stock drugs shall be supplied in individual doses unless the bulk container cannot be individualized. Dangerous drug floor stock
must be reviewed by the pharmacist or pharmacist intern on a routine basis to insure appropriate use
Which of the following drugs is classified as a Schedule III controlled drug?
a. Fioricet
b. Pentazocine
c. Codeine
d. Lorazepam
Answer: (a) Fioricet (Butalbital + Acetaminophen + Caffeine) is classified as a Schedule III drug, [New Mexico Administrative Code
(NMAC) 16.19.20.67(B)(d)].
.
.
.
Under the Federal Law, Fioricet (Butalbital + Acetaminophen + Caffeine) is classified as non-controlled substance whereas Fiorinal (Butalbital + Aspirin + Caffeine) is classified as a Schedule III controlled substance.
However, under the New Mexico State Pharmacy Law, both, Fioricet and Fiorinal are classified under Schedule III controlled
substances.
16.19.20.67(B)(d):
(1). Any compound, mixture or preparation containing:
(a). amobarbital;
(b). secobarbital;
(c). pentobarbital;
(d). butalbital; or any salt thereof and one or more active medicinal ingredients which are not listed in any schedule.
The pharmacist-in-charge is responsible for maintaining up-to-date reference materials or electronic access to reference publications commensurate with the scope of practice. At a minimum, the healthcare facility pharmacy shall carry:
I. a drug interactions text.
II. New Mexico Pharmacy Law and Rules and Regulations.
III. an injectable drug text.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.7.12].
A. The pharmacist-in-charge is responsible for provision of drug information to the staff and patients of the healthcare facility. The
pharmacist-in-charge shall be responsible for providing in-service education to the facilitys professional staff. In-service activities
shall be documented.
B. The pharmacist-in-charge is responsible for maintaining up-to-date reference materials or electronic access to reference
publications commensurate with the scope of practice. At a minimum, these references will include the current editions of:
(1). a drug interactions text;
(2). an injectable drug text;
(3). a general drug information text; and
(4). New Mexico Pharmacy Law and Rules and Regulations and all available revisions.
C. The telephone number of a regional Poison and Drug Information Center shall be posted in all areas where medications are
stored.
An emergency oral prescription for Schedule II controlled drugs must be mailed to dispensing pharmacy by an authorized prescriber
within:
a. 48 hours after an oral authorization.
b. 7 days after an oral authorization.
c. 10 days after an oral authorization.
d. 72 hours after an oral authorization.
Answer: (b) 7 days after an oral authorization. An emergency oral prescription for Schedule II controlled drugs must be written to
reduce and mailed to dispensing pharmacy by an authorized prescriber within 7 days after an oral authorization, [New Mexico
Administrative Code (NMAC) 16.19.20.47(B)(3)].
.
.
.
Emergency dispensing of Schedule II controlled substances. “Emergency situation” means the prescribing physician determines:
(1). that immediate administration of a controlled substance is necessary for proper treatment of the intended patient;
(2). that no appropriate alternative treatment is available, including administration of a drug which is not a controlled substance
under Schedule II; and
(3). that it is not reasonably possible for the prescribing practitioner to provide a written prescription to be presented to the person
dispensing the substance prior to the dispensing.
B. A pharmacy may dispense a Schedule II controlled substance in the above instance only if he receives oral authorization of a
practitioner or authorization via facsimile machine and provided:
(1). the quantity prescribed is limited to the amount needed to treat the patient during the emergency period;
(2). the pharmacist shall reduce the prescription to a written form and it contains all information required of a Schedule II controlled
substance prescription except the signature of the prescribing practitioner;
(3). the prescribing physician, within 7 days after authorization of the emergency dispensing, shall furnish a written, signed
prescription to the pharmacist.
The signed prescription shall have written on the face “AUTHORIZATION FOR EMERGENCY DISPENSING” and the date of the oral
order or facsimile order;
(4). the signed prescription shall be attached to the oral emergency prescription order or the facsimile emergency prescription order
and be filed as other Schedule II prescriptions.
What is the permissible ratio of pharmacy technicians to pharmacists on duty?
a. 2 to 1
b. 3 to 1
c. 4 to 1
d. Determined by Pharmacist-in-charge
Answer: (d) Determined by Pharmacist-in-charge, [New Mexico Administrative Code (NMAC) 16.19.22.10].
.
.
.
The permissible ratio of pharmacy technicians to pharmacists on duty is to be determined by the pharmacist in charge.
The board reserves the right to impose a ratio of pharmacy technicians to pharmacists if circumstances so dictate.
After dispensing an emergency oral Schedule II drug, the pharmacist shall contact which of the following upon not receiving a
written prescription from the prescriber within 7 days?
I. The DEA Office
II. The Board of Pharmacy
III. The Patient
a. I only
b. I and II only
c. II and III only
d. All
Answer: (b) I and II only, [New Mexico Administrative Code (NMAC) 16.19.20.20(C)].
.
.
.
After dispensing an emergency Schedule II drug, the pharmacist shall contact the DEA office and New Mexico State Board of
Pharmacy upon not receiving a written prescription from the prescriber within 7 days of an emergency oral authorization.
All technicians are required to obtain board approved certification within one year of registration with the board as a technician.
a. True
b. False
Answer: (a) True, [New Mexico Administrative Code (NMAC) 16.19.22.9(E)].
The pharmacist-in-charge shall ensure that the pharmacy technician has completed initial training which includes:
(1). federal and state laws and regulations that affect pharmacy practice; specific regulations which address the use of supportive
personnel and technicians;
(2). ethical and professional standards of practice;
(3). medical and pharmaceutical terminology, symbols and abbreviations used in the practice of pharmacy and components of a
prescription;
(4). pharmaceutical calculations necessary for the preparation and dispensing of drug products;
(5). manufacturing, preparation, packaging, labeling and proper storage of drug products;
(6). dosage forms and routes of administration; and
(7). trade and generic names for medications frequently dispensed by the pharmacy;
(8). basic comprehension of pharmacology;
(9). basic knowledge of appropriate pharmacy references.
B. If the duties of the technician will include the preparation of sterile products then, in addition to the training and education
requirements listed in this section, the technician will complete training outlined in Paragraph (2) of Subsection C of 16.19.6.11
NMAC.
C. A written record of training and education will be maintained by the pharmacy technician and contain the following:
(1). name of person receiving the training;
(2). date(s) of the training;
(3). description of the topics covered;
(4). names of the person(s) who provided the training; and
(5). signature of the technician and the technician training sponsor.
D. A written record of training and education must be submitted to the board with certification exam documentation to obtain
certified pharmacy technician registration.
E. All technicians are required to obtain board approved certification within one year of registration with the board as a technician.
F. The pharmacist-in-charge shall be responsible for the implementation of policies and procedures for additional training appropriate to duties and responsibilities performed by a pharmacy technician as well as an ongoing quality assurance plan to assure competency.
What are the requirements to become a licensed nuclear pharmacist, according to New Mexico State Pharmacy Law?
I. Must meet a minimum of 250 contact hours of didactic instruction in nuclear pharmacy and the safe handling and use of radioactive materials from a nationally accredited college of pharmacy.
II. Must have attained a minimum of 500 contact hours of experiential training in nuclear pharmacy under the supervision of a
qualified nuclear pharmacist.
III. Must obtain 50 hours in the clinical use of radiopharmaceuticals.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.18.7(C)].
“Qualified Nuclear Pharmacist” means a pharmacist currently licensed by the Board who meets either of the following criteria:
(1). Must be currently certified as a Nuclear Pharmacist by the Board of Pharmaceutical Specialties; or
(2). Must have met a minimum of 250 contact hours of didactic instruction in nuclear pharmacy and the safe handling and use of
radioactive materials from a nationally-accredited college of pharmacy or other training program sponsored by an ACPE-accredited
provider of continuing pharmaceutical education, with the minimum 250 contact hours.
(a). Must have attained a minimum of 500 contact hours of experiential training in nuclear pharmacy under the supervision of a
qualified nuclear pharmacist in, but not limited to, the following areas:
(i). Procurement of radioactive materials;
(ii). Compounding of radiopharmaceuticals;
(iii). Maintenance of a quality assurance program;
(iv). Dispensing of radiopharmaceuticals;
(v). Distribution of radiopharmaceuticals;
(vi). Implementation of basic health and safety practices and procedures;
(vii). Provision of information and consultation related to the practice of nuclear pharmacy and the use of radiopharmaceuticals;
(viii). Monitoring of outcomes in patients who receive radiopharmaceuticals and related ancillary medications;
(ix). Research and development of radiopharmaceuticals.
(b). 200 hours in the following five areas:
(i). Radiation physics and instrumentation;
(ii). Radiation protection;
(iii). Mathematics pertaining to the use and measurement of radioactivity;
(iv). Radiation biology;
(v). Radiopharmaceutical chemistry; and
(c). 50 hours in the clinical use of radiopharmaceuticals
Clinic drug stock may be dispensed by the pharmacy if:
I. the drugs are dispensed only to a clinic patient with a valid prescription from a practitioner of that clinic.
II. clinic prescriptions for clinic drugs are maintained separately from other prescriptions of the pharmacy.
III. the prescription is dispensed in a container with a label attached which reads “DISPENSED FOR (clinic name and address) BY
(pharmacy name and address)”.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.10.11(Q)].
.
.
.
Clinic drug stock may be transferred to, and maintained by, a pharmacy for dispensing to clinic patients as provided in this
regulation. Clinic drug stock may be dispensed by the pharmacy if:
(1). the drugs are dispensed only to a clinic patient with a valid prescription from a practitioner of that clinic;
(2). clinic prescriptions for clinic drugs are maintained separately from other prescriptions of the pharmacy;
(3). the prescription is dispensed in a container with a label attached which reads “DISPENSED FOR (clinic name and address) BY
(pharmacy name and address)”
(4). all packaging and labeling requirements for prescriptions dispensed by a pharmacy have been met; and
(5). patient records and counseling requirements have been maintained separately for all clinic patients whose prescriptions were
filled by the pharmacy from clinic drug stock.
Repackaging of drug from bulk containers into multiple dispensing units for future distribution to clinic patients at the site of
repackaging may be done by:
I. a physician
II. a pharmacist
III. a pharmacy technician
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.10.11(F)].
Repackaging of drug from bulk containers into multiple dispensing units for future distribution to clinic patients at the site of
repackaging may be done by a physician, dentist, pharmacist, or by a pharmacy technician under the supervision of the pharmacist
as defined in Subsection B of 16.19.22.7 NMAC. All drugs repackaged into multiple dispensing units by a pharmacy technician must
undergo a final check by the pharmacist.
(3). A record of drugs repackaged must be maintained, to include the following.
(a). Date of repackaging.
(b). Name and strength of drug.
(c). Lot number or control number.
(d). Name of drug manufacturer.
(e). Expiration date (per USP requirements).
(f). Total number of dosage units (tabs, caps) repackaged (for each drug).
(g). Quantity per each repackaged unit container.
(h). Number of dosage units (tabs, caps) wasted.
(i). Initials of repackager.
(j). Initials of person performing final check.
(4). All dispensing units of repackaged medication must be labeled with the following information.
(a). Name, strength, and quantity of the drug.
(b). Lot number or control number.
(c). Name of manufacturer.
(d). Expiration date.
(e). Date drug was repackaged.
(f). Name or initials of repackager.
(g). Federal caution label, if applicable.
(5). Repackaged units must be stored with the manufacturers package insert until relabeled for dispensing.
Repackaging from bulk containers to dispensing units for distribution at locations other than the site of repackaging requires FDA
registration, whether or not the repackaged drugs enter interstate commerce.
A pharmacist clinician DOES NOT have to obtain and review a PMP report before prescribing, ordering, or dispensing a controlled
substance in Schedule II, III or IV for a patient:
I. residing in a skilled nursing facility.
II. residing in a hospice care.
III. picking up a prescription from hospital outpatient pharmacy.
a. I only
b. I and II only
c. All
d. None of the above
Answer: (b) I and II only, [New Mexico Administrative Code (NMAC) 16.19.4.17(F)(1)(e)].
.
.
.
A pharmacist clinician does not have to obtain and review a PMP report before prescribing, ordering, or dispensing a controlled
substance in Schedule II, III or IV;
(i). to a patient in a nursing facility; or
(ii). to a patient in hospice care.
The Nursing-Home facility shall have a Medication Administration Record (MAR) documenting medications administered to residents. This documentation shall include:
I. Name of the OTC products used by residents.
II. Route of administration of prescribed drugs.
III. Dates when the medication is discontinued or changed.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.11.8(B)(4)(d)].
The facility shall have a Medication Administration Record (MAR) documenting medications administered to residents, including
over-the-counter medications. This documentation shall include:
(i). Name of resident;
(ii). Date given;
(iii). Drug product name;
(iv). Dosage and form;
(v). Strength of drug;
(vi). Route of administration;
(vii). How often medication is to be taken;
(viii). Time taken and staff initials;
(ix). Dates when the medication is discontinued or changed;
(x). The name and initials of all staff administering medications.
According to New Mexico State Pharmacy Law, a prescription may be issued in order for a practitioner to obtain controlled
substances for supplying the practitioner for the purpose of general dispensing to patients.
a. True
b. False
Answer: (b) False, [New Mexico Administrative Code (NMAC) 16.19.20.41(B)].
A. A prescription for a controlled substance may be issued for a legitimate medical purpose by an individual practitioner acting in the
usual course of his professional practice, and who is registered under the Controlled Substances Act.
The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a
corresponding responsibility rests with the pharmacist who fills the prescription.
B. A prescription may not be issued in order for a practitioner to obtain controlled substances for supplying the practitioner for the
purpose of general dispensing to patients.
C. A prescription may not be issued for the dispensing of narcotic drugs listed in any schedule to a narcotic dependent person for the
sole purpose of continuing his dependence upon such drugs.
D. A prescription may not be issued for the dispensing of the narcotic drugs listed in any schedule to a narcotic drug-dependent
person in the course of conducting an authorized clinical investigation in the development of a narcotic addict rehabilitation
program.
What are approved dangerous stock drugs for a Nursing Home facility?
I. Hepatitis B vaccine
II. Tuberculin testing solution
III. Sterile normal saline and water - irrigation
.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.11.8(B)(6)].
Stock dangerous drugs acquired, maintained and administered by the nursing home shall be listed in the nursing home policy and
procedure manual and approved by the Board of Pharmacy. The stock dangerous drugs shall be used when a licensed nurse (LPN or
RN) is on duty. The following is the approved list of stock dangerous drugs:
(i). Sterile normal saline and water - injectable;
(ii). Sterile normal saline and water - irrigation;
(iii). Tuberculin testing solution;
(iv). Vaccines as recommended by the centers for disease control (CDC) and prevention’s advisory committee on immunization
practices and appropriate for the facility population served;
(v). Any additional dangerous drugs must be defined and listed in the policy and procedure manual and must be approved by the
Board of Pharmacy prior to obtaining or using.
Which of the following indicates a controlled substance abusing by a patient while reviewing the patients PMP report by a pharmacist?
I. opioids from multiple prescribers.
II. opioids and benzodiazepines concurrently.
III. requests to pay cash when insurance is available.
a. I only
b. I and II only
c. II and III only
d. All
Answer: (d) All, [New Mexico Administrative Code (NMAC) 16.19.4.17(F)(1)(f)].
.
.
.
The following indicates or suggests that the patient may be abusing controlled substances while reviewing his/her PMP report by the
pharmacist.
(i). opioids from multiple prescribers;
(ii). opioids and benzodiazepines concurrently;
(iii). opioids for more than 12 consecutive weeks;
(iv). more than one controlled substance analgesic;
(v). opioids totaling more than 90 morphine milligram equivalents per day;
(vi). exhibiting potential for abuse of misuse of opioids and other controlled substances, such as over-utilization, requests to fill
early, requests for specific opioids, requests to pay cash when insurance is available, receiving opioids from multiple pharmacies.
Upon recognizing any of the above conditions the pharmacist clinician using professional judgement based on prevailing standards
of practice, shall take action as appropriate to prevent, mitigate, or resolve any potential problems or risks that may result in opioid
misuse, abuse, or overdose.
These steps may involve counseling the patient on known risks and realistic benefits of opioid therapy, prescription and training for
naloxone, consultation with or referral to a pain management specialist, offering or arranging treatment for opioid or substance use disorder; the pharmacist clinician shall document actions taken to prevent, mitigate, or resolve the potential problems or risks.
May a skilled nursing facility stock the sample of prescription drugs to be administered by the facilities designated personnel?
a. Yes
b. No
Answer: (b) No, [New Mexico Administrative Code (NMAC) 16.19.11.8(7)(h)].
.
.
.
Licensed Facility: Any facility, skilled nursing facility, intermediate care or any other upper level of care facility as defined by Health
and Human Services Department that is required to maintain custody of patients drugs in a drug room, and such drugs are
administered by the facilities' designated personnel.
No drug samples shall be stocked in the licensed facility.
